Cargando…
Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?
BACKGROUND: In the absence of liver biopsy, the World Health Organization recommends non‐invasive tests, such as aspartate aminotransferase to platelet ratio index and FIB‐4, to assess liver fibrosis in patients with chronic hepatitis B. However, these tests are not well validated in sub‐Saharan Afr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637891/ https://www.ncbi.nlm.nih.gov/pubmed/28222249 http://dx.doi.org/10.1111/liv.13393 |
_version_ | 1783270668314345472 |
---|---|
author | Desalegn, Hailemichael Aberra, Hanna Berhe, Nega Gundersen, Svein G. Johannessen, Asgeir |
author_facet | Desalegn, Hailemichael Aberra, Hanna Berhe, Nega Gundersen, Svein G. Johannessen, Asgeir |
author_sort | Desalegn, Hailemichael |
collection | PubMed |
description | BACKGROUND: In the absence of liver biopsy, the World Health Organization recommends non‐invasive tests, such as aspartate aminotransferase to platelet ratio index and FIB‐4, to assess liver fibrosis in patients with chronic hepatitis B. However, these tests are not well validated in sub‐Saharan Africa. Recently, a new marker, gamma‐glutamyl transpeptidase to platelet ratio, was found to be more accurate in an African setting, but this needs confirmation in other cohorts. METHODS: A treatment program for chronic hepatitis B was initiated in Addis Ababa, Ethiopia, in 2015. Non‐invasive tests were compared with transient elastography (Fibroscan 402, Echosense, France) using the following thresholds: no fibrosis (≤7.9 kPa), significant fibrosis (>7.9 kPa) and cirrhosis (>11.7 kPa). The diagnostic accuracy was estimated by calculating the area under the receiver operating characteristics curve. RESULTS: Of 582 treatment‐naïve patients, 141 (24.2%) had significant fibrosis and 90 (15.5%) had cirrhosis. The area under the receiver operating characteristics curve of aspartate aminotransferase to platelet ratio index, FIB‐4 and gamma‐glutamyl transpeptidase to platelet ratio was high both to diagnose significant fibrosis (0.79 [95% CI 0.75‐0.84], 0.79 [95% CI 0.75‐0.84], 0.80 [95% CI 0.75‐0.85]) and cirrhosis (0.86 [95% CI 0.81‐0.91], 0.86 [95% CI 0.81‐0.91], 0.87 [95% CI 0.82‐0.91]). The specificity was high for all tests (94%‐100%); however, the sensitivity was poor both to detect fibrosis (10%‐45%) and cirrhosis (10%‐36%). CONCLUSIONS: Aspartate aminotransferase to platelet ratio index, FIB‐4 and gamma‐glutamyl transpeptidase to platelet ratio had good diagnostic properties to detect liver fibrosis and cirrhosis in patients with chronic hepatitis B in East Africa. However, the sensitivity was low, and only 10% of patients with cirrhosis were detected using aspartate aminotransferase to platelet ratio index at the World Health Organization recommended threshold. |
format | Online Article Text |
id | pubmed-5637891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56378912017-10-25 Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? Desalegn, Hailemichael Aberra, Hanna Berhe, Nega Gundersen, Svein G. Johannessen, Asgeir Liver Int Viral Hepatitis BACKGROUND: In the absence of liver biopsy, the World Health Organization recommends non‐invasive tests, such as aspartate aminotransferase to platelet ratio index and FIB‐4, to assess liver fibrosis in patients with chronic hepatitis B. However, these tests are not well validated in sub‐Saharan Africa. Recently, a new marker, gamma‐glutamyl transpeptidase to platelet ratio, was found to be more accurate in an African setting, but this needs confirmation in other cohorts. METHODS: A treatment program for chronic hepatitis B was initiated in Addis Ababa, Ethiopia, in 2015. Non‐invasive tests were compared with transient elastography (Fibroscan 402, Echosense, France) using the following thresholds: no fibrosis (≤7.9 kPa), significant fibrosis (>7.9 kPa) and cirrhosis (>11.7 kPa). The diagnostic accuracy was estimated by calculating the area under the receiver operating characteristics curve. RESULTS: Of 582 treatment‐naïve patients, 141 (24.2%) had significant fibrosis and 90 (15.5%) had cirrhosis. The area under the receiver operating characteristics curve of aspartate aminotransferase to platelet ratio index, FIB‐4 and gamma‐glutamyl transpeptidase to platelet ratio was high both to diagnose significant fibrosis (0.79 [95% CI 0.75‐0.84], 0.79 [95% CI 0.75‐0.84], 0.80 [95% CI 0.75‐0.85]) and cirrhosis (0.86 [95% CI 0.81‐0.91], 0.86 [95% CI 0.81‐0.91], 0.87 [95% CI 0.82‐0.91]). The specificity was high for all tests (94%‐100%); however, the sensitivity was poor both to detect fibrosis (10%‐45%) and cirrhosis (10%‐36%). CONCLUSIONS: Aspartate aminotransferase to platelet ratio index, FIB‐4 and gamma‐glutamyl transpeptidase to platelet ratio had good diagnostic properties to detect liver fibrosis and cirrhosis in patients with chronic hepatitis B in East Africa. However, the sensitivity was low, and only 10% of patients with cirrhosis were detected using aspartate aminotransferase to platelet ratio index at the World Health Organization recommended threshold. John Wiley and Sons Inc. 2017-03-23 2017-10 /pmc/articles/PMC5637891/ /pubmed/28222249 http://dx.doi.org/10.1111/liv.13393 Text en © 2017 The Authors. Liver International Published by John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Viral Hepatitis Desalegn, Hailemichael Aberra, Hanna Berhe, Nega Gundersen, Svein G. Johannessen, Asgeir Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? |
title | Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? |
title_full | Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? |
title_fullStr | Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? |
title_full_unstemmed | Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? |
title_short | Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? |
title_sort | are non‐invasive fibrosis markers for chronic hepatitis b reliable in sub‐saharan africa? |
topic | Viral Hepatitis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637891/ https://www.ncbi.nlm.nih.gov/pubmed/28222249 http://dx.doi.org/10.1111/liv.13393 |
work_keys_str_mv | AT desalegnhailemichael arenoninvasivefibrosismarkersforchronichepatitisbreliableinsubsaharanafrica AT aberrahanna arenoninvasivefibrosismarkersforchronichepatitisbreliableinsubsaharanafrica AT berhenega arenoninvasivefibrosismarkersforchronichepatitisbreliableinsubsaharanafrica AT gundersensveing arenoninvasivefibrosismarkersforchronichepatitisbreliableinsubsaharanafrica AT johannessenasgeir arenoninvasivefibrosismarkersforchronichepatitisbreliableinsubsaharanafrica |